Fotokoagulacja laserowa czy terapia doszklistkowa – dylematy w leczeniu cukrzycowego obrzęku plamki

• Authors: Maciej Gawęcki

Title variants

EN

Laser photocoagulation or intravitreal therapy – dilemma concerning treatment of diabetic macular edema

• Languages of publication: PL

Abstracts

PL

Leczenie cukrzycowego obrzęku plamki stanowi dla lekarza okulisty wyzwanie terapeutyczne. Jeszcze niedawno główną metodą leczenia tego schorzenia była fotokoagulacja laserowa siatkówki, która zwykle nie prowadziła do znaczącej poprawy widzenia. Współcześnie mamy do dyspozycji skuteczne, ale kosztowne terapie doszklistkowe, w których stosuje się preparaty anty-VEGF i leki sterydowe. Dodatkowo na rynku pojawiły się lasery mikropulsowe niepowodujące uszkodzenia siatkówki. W tym kontekście niezbędne wydają się stworzenie nowego schematu leczenia cukrzycowego obrzęku plamki oraz zmiana sposobu myślenia o roli fotokoagulacji laserowej w tym procesie terapeutycznym.

EN

For an ophthalmologist, treatment of diabetic macular edema is a therapeutic challenge. Up to recently, the leading method of treatment of this clinical entity was laser photocoagulation, which in most cases didn’t result in improvement of vision. At present, at our disposal are effective, but expensive, intravitreal therapies by anti-VEGF and steroid medications. Additionally, micropulse lasers, that do not damage the retina, emerged on the market. In this context, it is necessary to create a new algorithm of treatment of diabetic macular edema, as well as change our way of thinking about the role of laser photocoagulation in treating of DME.

Keywords

EN

cukrzycowy obrzęk plamki; laseroterapia; terapia anty-VEGF

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OphthaTherapy
• Year: 2014
• Volume: 1
• Issue: 2
• Pages: 68-75

Contributors

author

Maciej Gawęcki

• Poradnia Okulistyczna Dobry Wzrok w Gdańsku Oddział Okulistyczny, Szpital Specjalistyczny w Chojnicach

References

• 1. Klein R., Klein B., Moss S. et al.: The Wisconsin epidemiologic study of diabetic retinopathy: the long-term incidence of macular edema. Ophthalmology 1995; 102: 7-16.
• 2. Klein R., Klein B., Moss S. et al.: Diabetic macular edema. Ophthalmology 1984; 91:1464-1474.
• 3. van Leiden H. et al.: Risk factors for incident retinopathy in a diabetic and nondiabetic population. The Hoorn Study. Arch. Ophthalmol. 2003; 121: 245-251.
• 4. Gordon B., Chang S., Kavanagh M. et al.: The effects of lipid lowering on diabetic retinopathy. Am. J. Ophthalmol. 1991; 112: 385-391.
• 5. Early Treatment Diabetic Retinopathy Study research group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch. Ophthalmol. 1985; 103: 1796-1806.
• 6. Early Treatment Diabetic Retinopathy Study research group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Arch. Ophthalmol. 1987; 94: 761-74.
• 7. Lee C., Olk R.J.: Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991; 98: 1594-602.
• 8. Vujosevic S., Bottega E., Casciano M. et al.: Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina 2010; 30(6): 908-16.
• 9. Luttrull J.K., Dorin G.: Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review: Curr. Diabetes Rev. 2012; 8(4): 274-84.
• 10. Beck R.W., Edwards A.R., Aiello L. et al.: Diabetic Retinopathy Clinical Research Network (DRCR.net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch. Ophthalmol. 2009; 127: 245-51.
• 11. Haller J.A., Kuppermann B.D., Blumenkranz M.S. et al.: Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch. Ophthalmol. 2010; 128: 289-96.
• 12. Campochiaro P.A., Brown D.M., Pearson A. et al.: Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118: 626-35.
• 13. Pearson P.A., Comstock T.L., Ip M. et al.: Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118: 1580-7.
• 14. Massin P., Bandello F., Garweg J.G. et al.: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33: 2399-405.
• 15. Nguyen Q.D., Shah S.M., Khwaja A.A. et al.: Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010; 117: 2146-51.
• 16. Mitchell P., Bandello F., Schmidt-Erfurth U. et al.: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-25.
• 17. Aiello L.P., Beck R.W., Bressler N.M. et al.: Diabetic Retinopathy Clinical Research Network; Writing Committee: Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology 2011; 118(12): 5-14.
• 18. Mitchell P.; RESTORE extension study group.: 2-Year safety and efficacy outcome of ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (DME): an interim analysis of the RESTORE extension study. Invest. Ophthalmol. Vis. Sci. 2012; 53: E-Abstract 4667.
• 19. Soheilian M., Ramezani A., Obudi A. et al.: Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116: 1142-50.
• 20. Nepomuceno A.B., Takaki E., Paes de Almeida F.P. et al.: A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema: Am. J. Ophthalmol. 2013; 156(3): 502-10.
• 21. Lam D.S., Lai T.Y., Lee V.Y. et al.: Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina 2009; 29: 292-9.
• 22. Michaelides M., Fraser-Bell S., Hamilton R. et al.: Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): report 1. Retina 2010; 30: 781-6.
• 23. Do D.V., Schmidt-Erfurth U., Gonzalez V.H. et al.: The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011; 118: 1819-26.
• 24. Patel J.I., Hykin P.G., Schadt M. et al.: Pars plana vitrectomy with and without peeling of inner retinal membrane for diabetic macular edema. Retina 2006; 26: 5-13.
• 25. Figueroa M.S., Contreras I., Noval S.: Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina 2008; 28: 420-426.
• 26. Joussen A.M., Joeres S.: Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema. Dev. Ophthalmol. 2007; 39: 69-87.
• 27. Polskie Towarzystwo Okulistyczne. Zasady postępowania w cukrzycowym obrzęku plamki [online: www.pto.com.pl/dokumenty/ pobierz/45,wytyczne-pto--leczenie-dme-2014].
• 28. Royal College of Ophthalmologist.: Diabetic Retinopathy Guidelines, December 2012 [online: http://www.icoph.org/dynamic/ attachments/taskforce_documents/2012-sci-267_diabetic_retinopathy_guidelines_december_2012.pdf].
• 29. Mansour S., Luttrull J.: Integration of MicroPulse Laser Therapy (MPLT) in the Management of Diabetic Retinopathy. [Materiały konferencyjne: IRIDEX Educational Webinar 2012].

• Document Type: article